| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.0021 | 0.9 |